Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-48

One would have thought that we would be a lot further down the road by now given those initial findings!? - goes to show how slow things move in the Biotech space and how much patience is required!
"Conclusions:

In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunological disorders.
Classification:

This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions."

"ATL1102, which employs a unique antisense mechanism to reduce VLA-4 expression, has in this study substantially reduced disease activity in RRMS at doses that are generally well-tolerated. Longer-term trials are required to confirm its potential as a valuable additional therapeutic option in the treatment of RRMS."

Thanks for the refresher Gassy

Cheers
.